There are over 15 disease-modifying drugs that have been approved over the last 20 years
for the treatment of relapsing–remitting multiple sclerosis (MS), but there are limited …

There is significant interest in understanding inflammatory responses within the brain and
spinal cord. Inflammatory responses that are centralized within the brain and spinal cord are …

The ability to control autoreactive T cells without inducing systemic immune suppression is
the major goal for treatment of autoimmune diseases. The key challenge is the safe and …

Astrocytes form borders (glia limitans) that separate neural from non-neural tissue along
perivascular spaces, meninges and tissue lesions in the CNS. Transgenic loss-of-function …

Myelin oligodendrocyte glycoprotein (MOG)-associated disease (MOGAD) is a rare,
antibody-mediated inflammatory demyelinating disorder of the central nervous system …

Background Multiple sclerosis is an acquired demyelinating disease of the central nervous
system. It is the second most common cause of disability in adults in United States after head …

It has been more than 100 years since Paul Ehrlich reported that various water-soluble dyes
injected into the circulation did not enter the brain. Since Ehrlich's first experiments, only a …

Experimental autoimmune encephalomyelitis (EAE) is the most commonly used
experimental model for the human inflammatory demyelinating disease, multiple sclerosis …

Multiple sclerosis (MS) is universally found to be more prevalent in women than men. This
has led to extensive studies of differences in the immune system or nervous system between …

Inflammation and oxidative stress are thought to promote tissue damage in multiple
sclerosis. Thus, novel therapeutics enhancing cellular resistance to free radicals could prove …